These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Renal cancer genetics: von Hippel Lindau and other syndromes. Fleming S Int J Dev Biol; 1999; 43(5):469-71. PubMed ID: 10535326 [TBL] [Abstract][Full Text] [Related]
5. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Aydin H; Chen L; Cheng L; Vaziri S; He H; Ganapathi R; Delahunt B; Magi-Galluzzi C; Zhou M Am J Surg Pathol; 2010 Nov; 34(11):1608-21. PubMed ID: 20924276 [TBL] [Abstract][Full Text] [Related]
6. Inactivation of BHD in sporadic renal tumors. Khoo SK; Kahnoski K; Sugimura J; Petillo D; Chen J; Shockley K; Ludlow J; Knapp R; Giraud S; Richard S; Nordenskjöld M; Teh BT Cancer Res; 2003 Aug; 63(15):4583-7. PubMed ID: 12907635 [TBL] [Abstract][Full Text] [Related]
7. [Renal cell carcinoma molecular biology. Prognostic and therapeutic usefulness]. Zudaire Bergera JJ; Rincón Mayans A; Rioja Zuazu J; Barba Abad J; Romero Vargas L; Algarra Navarro R; Tienza Fernández A; Robles García JE; Rosell Costa D; Berián Polo JM; Pascual Piédrola JI Arch Esp Urol; 2013; 66(1):23-32. PubMed ID: 23406797 [TBL] [Abstract][Full Text] [Related]
8. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Harshman LC; Choueiri TK Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513 [TBL] [Abstract][Full Text] [Related]
9. Non-clear cell advanced kidney cancer: is there a gold standard? Sánchez P; Calvo E; Durán I Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605 [TBL] [Abstract][Full Text] [Related]
10. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Gnarra JR; Lerman MI; Zbar B; Linehan WM Semin Oncol; 1995 Feb; 22(1):3-8. PubMed ID: 7855617 [TBL] [Abstract][Full Text] [Related]
11. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens. Zhuang Z; Gnarra JR; Dudley CF; Zbar B; Linehan WM; Lubensky IA Mod Pathol; 1996 Aug; 9(8):838-42. PubMed ID: 8871925 [TBL] [Abstract][Full Text] [Related]
12. Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors. Kim CM; Vocke C; Torres-Cabala C; Yang Y; Schmidt L; Walther M; Linehan WM J Urol; 2006 May; 175(5):1908-14. PubMed ID: 16600797 [TBL] [Abstract][Full Text] [Related]
14. Rational therapy for renal cell carcinoma based on its genetic targets. Messer J; Drabick J; Kaag M Adv Exp Med Biol; 2013; 779():291-308. PubMed ID: 23288645 [TBL] [Abstract][Full Text] [Related]
15. Papillary renal cell carcinoma: A review of the current therapeutic landscape. Courthod G; Tucci M; Di Maio M; Scagliotti GV Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049 [TBL] [Abstract][Full Text] [Related]